EE525 the Economic Value of Insulin Glargine 300 U/Ml (Gla-300) in People ≥18 Years of Age with Type 2 Diabetes Mellitus: A Value-Based Economic Model from a U.S. Payer Perspective

Previous real-world evidence (RWE) studies have demonstrated lower healthcare resource utilization (HCRU) in Type II diabetes (T2DM) patients who switched from 1st generation to 2nd generation basal insulin (BI) therapies. This study assessed the value and affordability of Gla-300 in a value-based economic model by leveraging the RWE from a U.S. payer perspective.